InflaRx
InflaRx is a biopharmaceutical company pioneering a new approach to treating acute, life-threatening, and chronic inflammatory diseases.
/10
Transparency ranking
Work at InflaRx?
Tell us what we're missing about working at InflaRx so we can make the job search more transparent for everyone.
Tell us what it's like to work at InflaRx!Description
InflaRx is a biopharmaceutical company headquartered in Jena, Germany, focused on developing highly specific therapeutics targeting the C5a/C5aR signaling axis of the complement system. This system plays a crucial role in the body's immune response, and InflaRx is developing new inhibitors to control acute, life-threatening, and chronic inflammatory diseases. Their flagship drug, vilobelimab, is a first-in-class anti-human C5a monoclonal antibody currently in development for various conditions, including chronic inflammatory diseases, oncology, and critically ill COVID-19 patients.
InflaRx is committed to making life-saving treatments available to patients. The company has received an Emergency Use Authorization (EUA) from the FDA for Gohibic (vilobelimab) to treat certain critically ill COVID-19 patients. Notably, InflaRx has implemented the InflaRx Commitment program, offering a full refund for Gohibic administered to patients who meet specific criteria, including ICU death due to COVID-19 complications. This initiative demonstrates the company's dedication to supporting healthcare institutions and ensuring patient access to their potentially life-saving therapies.
Mission
InflaRx is a biopharmaceutical company dedicated to developing highly specific therapeutics targeting the C5a/C5aR signaling axis of the complement system. Their focus is on addressing diseases with high unmet medical need, particularly acute, life-threatening, and chronic inflammatory diseases. They strive to control inflammation by creating new and selective inhibitors of the C5a/C5aR signaling pathway, a crucial element of the immune system's complement cascade.
Culture
InflaRx promotes a collaborative and results-oriented culture. They emphasize teamwork, with highly motivated and skilled individuals working together to achieve common goals. Their commitment to innovation and development of new medicines for inflammatory diseases drives their dedication to excellence, fostering a dynamic and challenging environment where employees can contribute meaningfully to the advancement of healthcare.
DE&I
InflaRx's website does not provide a statement about its approach to diversity, equity, and inclusion.
Similar companies. But verified.
